Novartis Reports post-marketing Data for Bevacizumab in Hemophilia A

Novartis today announced post-marketing results for bevacizumab in patients with hemophilia A. The study demonstrated that bevacizumab reduces disease progression risk compared to standard of care or placebo. These results provide important insights into the treatment of hemophilia A and support the continued development of bevacizumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.